Amylyx Pharmaceuticals announced the pricing of an upsized underwritten public offering of common stock this week [1].
This capital raise provides a significant liquidity boost for the biotechnology firm, allowing it to strengthen its balance sheet as it navigates the costly process of drug development and commercialization.
The company is offering 14,090,000 shares [1] of its common stock. This volume of shares is described as an upsized offering, indicating that investor demand exceeded the initial amount the company intended to sell [2].
Reports on the specific price per share vary slightly between financial news outlets. Yahoo Finance said the public offering price was $35 per share [1], while MSN said the price was $35.50 per share [2].
Amylyx expects the total gross proceeds from the offering to reach $500 million [2]. The company is listed on the Nasdaq exchange in the U.S. [3].
The offering is underwritten, meaning financial institutions have committed to purchasing the shares from the company to resell them to the public. This structure reduces the risk for the issuer by guaranteeing a specific amount of capital regardless of immediate market fluctuations.
Detailed terms of the offering, including the final closing date and the specific underwriters involved, were not provided in the initial announcement [1]. The company's stock continues to trade under the ticker AMLX [3].
“Amylyx expects the total gross proceeds from the offering to reach $500 million [2].”
Upsizing a public offering typically suggests strong institutional appetite for a company's stock. For a pharmaceutical firm like Amylyx, securing $500 million in cash is a strategic move to fund clinical trials or expand market reach without incurring the interest costs associated with corporate debt.
